217 related articles for article (PubMed ID: 34949146)
1. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
Chen C; Lu D; Sun T; Zhang T
Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
3. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
[TBL] [Abstract][Full Text] [Related]
5. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
6. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
Dai J; Yang L; Addison G
Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
9. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
10. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
11. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
[TBL] [Abstract][Full Text] [Related]
14. Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors.
Zhong HA; Almahmoud S
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047004
[TBL] [Abstract][Full Text] [Related]
15. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
Gonzalez Lopez de Turiso F; Guckian K
Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
[TBL] [Abstract][Full Text] [Related]
16. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
17. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
19. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
De SK
Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
[TBL] [Abstract][Full Text] [Related]
20. Mucosal Epithelial Jak Kinases in Health and Diseases.
Kumar N; Kuang L; Villa R; Kumar P; Mishra J
Mediators Inflamm; 2021; 2021():6618924. PubMed ID: 33814980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]